Dairy-Free Baby Formula: Options for Infants with Cow's Milk Allergy

Cow's milk protein allergy (CMPA) is the most common food allergy in infants, affecting approximately 2 to 3% of babies in the first year of life, according to research published in the journal Pediatric Allergy and Immunology. Unlike lactose intolerance (which is an enzyme deficiency), CMPA is a genuine immune response to one or more proteins in cow's milk, primarily casein and beta-lactoglobulin. For formula-fed infants, this means standard cow's milk-based formulas are unsuitable and can cause significant symptoms ranging from skin rashes and digestive distress to more severe reactions. Fortunately, a well-developed range of specialist formulas now exists, and with the right medical guidance, infants with CMPA can be safely and adequately nourished from birth through the first year and beyond.

Prevalence and Who It Affects

CMPA typically manifests in the first weeks to months of life, when cow's milk proteins are first introduced via formula feeding. Breastfed infants can also develop CMPA if cow's milk proteins from the mother's diet pass through breast milk in sufficient quantities, though this is less common and typically produces milder symptoms. The allergy is more prevalent in infants with a family history of atopic conditions (eczema, asthma, hay fever, or other food allergies). A 2019 systematic review in the British Journal of Nutrition estimated UK CMPA prevalence at around 2%, though parent-reported prevalence is considerably higher, reflecting diagnostic uncertainty and symptom overlap with other conditions.

Recognising the Symptoms

CMPA presents through three main systems, and symptoms can appear immediately after exposure (IgE-mediated, within minutes to 2 hours) or with a delay of several hours to days (non-IgE-mediated or mixed). This distinction matters clinically because the two types require different diagnostic approaches and carry different implications for reintroduction.

Gastrointestinal Symptoms

• Frequent vomiting or posseting beyond the typical amount for age
• Persistent diarrhoea or loose, mucousy stools
• Blood in stools (a red flag symptom requiring urgent review)
• Constipation that does not respond to standard management
• Apparent pain and distress after feeding, beyond typical colic
• Failure to thrive (poor weight gain)

Skin Symptoms

• Eczema, particularly if severe or not well controlled by standard emollient treatment
• Urticaria (hives) in IgE-mediated reactions
• Facial swelling or lip swelling around the mouth (angioedema) in severe IgE reactions

Respiratory Symptoms

• Rhinitis (runny nose) or nasal congestion
• Wheeze or cough, particularly in more severe IgE-mediated cases

Anaphylaxis from CMPA in infants is rare but does occur in severe IgE-mediated cases and requires emergency treatment. Any infant showing rapid-onset symptoms involving two body systems simultaneously after milk exposure should receive emergency medical attention.

Diagnosis

CMPA diagnosis is primarily clinical in non-IgE-mediated presentations, based on a thorough dietary history and a structured dairy elimination trial. The standard approach recommended by the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the UK's National Institute for Health and Care Excellence (NICE, guideline CG116 from 2011, updated 2015) involves a 2 to 4 week elimination trial of cow's milk protein (by switching formula and, if breastfeeding, by maternal dairy exclusion), followed by a supervised reintroduction to confirm the diagnosis.

For suspected IgE-mediated CMPA, specific IgE blood tests (RAST) and skin prick tests are available through allergy clinics and can identify sensitisation to specific milk proteins, though a positive test confirms sensitisation rather than clinical allergy and must be interpreted alongside the history. Self-referral to a dietitian or allergy specialist is appropriate if the GP is unable to complete a full assessment.

Types of Dairy-Free Formula

Extensively Hydrolysed Formula (eHF)

This is the first-line specialised formula for most infants with CMPA, recommended by ESPGHAN and most national dietetic associations. In extensively hydrolysed formula, cow's milk proteins are broken down (hydrolysed) into very small peptide fragments that are too small to be recognised by the immune system in most allergic infants. The protein source is still ultimately cow's milk (either casein or whey), but the allergenic proteins are destroyed in the hydrolysis process.

The key products available in the UK include:

• Nutramigen with LGG (Mead Johnson / Reckitt): Casein-based eHF, one of the most widely prescribed formulas for CMPA in the UK. Contains the probiotic Lactobacillus rhamnosus GG (LGG), which some evidence (a 2015 randomised controlled trial in Pediatrics) suggests may accelerate tolerance development. Available on NHS prescription.
• Aptamil Pepti 1 and Pepti 2 (Danone Nutricia): Whey-based eHF, available in age-appropriate stages. Widely prescribed and accepted by most infants.
• Similac Alimentum (Abbott): Casein-based eHF used in UK and US, with a flavour profile similar to Nutramigen.
• Pregestimil (Mead Johnson): A casein-based eHF with medium-chain triglycerides (MCT), used specifically for infants with fat malabsorption alongside CMPA, such as those with cholestatic liver disease or short bowel syndrome.

Approximately 90 to 95% of infants with CMPA tolerate eHF. The remaining 5 to 10% (those with the most severe reactions or multiple food allergies) require an amino acid formula.

Amino Acid Formula (AAF)

Amino acid formulas (also called elemental formulas) contain no intact protein or peptides at all. Instead, the nitrogen source is individual free amino acids, the building blocks of protein, which carry no allergenic risk. These formulas are nutritionally complete and are used for infants who do not tolerate eHF, who have multiple food allergies, who have eosinophilic oesophagitis, or who have faltering growth on eHF.

The main amino acid formulas available in the UK include:

• Neocate LCP (Nutricia): The most widely used AAF in the UK, available on NHS prescription for confirmed CMPA where eHF has not been tolerated. Neocate contains long-chain polyunsaturated fatty acids (LCP) including DHA and ARA for brain and eye development.
• Alfamino (Nestlé Health Science): An AAF with a different fat blend, including MCT, used in similar clinical situations to Neocate. Has a slightly different taste profile that some infants accept better.
• Elecare (Abbott): Available in the UK and widely used in North America as an AAF for CMPA and other conditions requiring elemental nutrition.
• PurAmino (Mead Johnson / Reckitt): Formerly known as Nutramigen AA, available for severe CMPA.

Amino acid formulas are significantly more expensive than eHF (often £25 to £40 per tin in the UK), which is why they are typically available on NHS prescription following specialist confirmation of the indication. In the United States, they are often covered under Medicaid for qualifying infants but may require prior authorisation from private insurers.

Soy Formula

Soy-based infant formula (using soy protein as the nitrogen source) is dairy-free and available over the counter in the UK, US, and most countries. However, it is not the first-line recommendation for CMPA for several reasons. First, approximately 10 to 14% of infants with non-IgE-mediated CMPA also react to soy protein (cross-reactivity). Second, soy formula contains phytoestrogens (isoflavones), and while their clinical significance in infants is debated, the Committee on Toxicity in the UK recommended in 2003 that soy formula not be used in infants under 6 months of age without medical advice. ESPGHAN's 2006 position paper similarly advised caution. Third, soy formula is not recommended for preterm infants due to concerns about mineral bioavailability.

Soy formula is an option for some older infants (typically over 6 months) with IgE-mediated CMPA who have tested negative for soy allergy, or for families with vegetarian or vegan dietary preferences who have discussed it with a clinician. It should not be used as a first response to suspected CMPA without clinical guidance.

Accessing Specialist Formula on the NHS

In the UK, eHF and AAF are available on GP prescription for infants with confirmed or clinically suspected CMPA. The process typically involves:

1. Presenting symptoms to a GP with a detailed feeding history.
2. The GP initiating a supervised 2 to 4 week trial of an eHF (most commonly Nutramigen or Aptamil Pepti 1) with a maternal dairy-free diet if breastfeeding.
3. If symptoms resolve and return on reintroduction (either planned diagnostic reintroduction or accidental), the diagnosis is confirmed and prescription continues.
4. For cases not improving on eHF, or with multiple food allergies, referral to a paediatric dietitian or paediatric allergist is appropriate.

Families who encounter difficulty accessing specialist formula on prescription can contact the National Allergy Strategy Group or seek a referral to a paediatric allergy service. The charity Allergy UK provides a helpline (01322 619898) for parents navigating CMPA diagnoses.

When Can Cow's Milk Be Reintroduced?

The majority of children with CMPA develop tolerance naturally. Approximately 50% tolerate cow's milk by age 1, 75% by age 3, and 90% by age 6, according to data from the landmark 2007 study by Skripak et al. published in the Journal of Allergy and Clinical Immunology. Non-IgE-mediated CMPA resolves earlier and more completely than IgE-mediated CMPA.

Reintroduction is typically guided by the "milk ladder" protocol, developed by the iMAP (Milk Allergy in Primary Care) group and widely used in the UK. The milk ladder begins with baked milk (cow's milk protein in a thoroughly baked product such as a biscuit or cake), which is tolerated by approximately 75% of children with non-IgE-mediated CMPA before they tolerate fresh milk. Each rung of the ladder introduces milk in progressively less processed forms, from baked goods through to fresh milk, with a period of tolerance assessment between each step. The ladder should always be followed under dietitian guidance and, for IgE-mediated CMPA, under the supervision of an allergy specialist.

Related: Baby Formula Types: A Complete Guide | Lactose Intolerance in Infants: What Parents Need to Know